Abstract
Purpose
To assess the maternal and neonatal outcomes of pregnant women enrolled on a Methadone Substitution Programme (MSP).
Design
Retrospective cohort study.
Setting
Maternity unit of a London teaching hospital and tertiary referral centre.
Subjects
Pregnant women on a MSP whose antenatal care and delivery was at St Thomas’ Hospital (STH) between January 2005 and March 2008. Controls were non-MSP mothers closely matched for age, parity and delivery date during the same period.
Methods
Maternal data was collected from the Liaison Antenatal Drugs and Alcohol Service clinic records and the STH Maternity Unit’s computerised database. Neonatal data was extracted from the STH Neonatal database (part of the UK National Neonatal database).
Outcome measures
Maternal profiles (age, gravidity, parity, ethnicity, BMI, smoking and alcohol history, relationship and employment history), pregnancy details and mode of delivery. Neonatal outcome measures to include gestation age at delivery, birth weight, head circumference, admission rates and length of stay on Special Care Baby Unit plus Neonatal Abstinence Syndrome (NAS) rates, scoring and treatment.
Results
Compared to the non-MSP mothers (n = 88) the MSP group (n = 44) booked later and had a higher incidence of smoking (6.8 vs. 84.1 %), alcohol consumption (10.2 vs. 34.1 %). As a group, they had adverse social background. The MSP group had a higher relative risk (RR) of premature delivery [RR = 2.5, 95% confidence interval (CI) 1.66–3.88] and had lower birth weight babies (adjusted RR = 2.2; 95% CI 1.31–3.71) with smaller head circumferences (adjusted RR 1.9; 95% CI 1.06–3.38). NAS occurred in 27 % (95% CI 15.0–42.8) of the MSP group. There was no difference in congenital abnormality between the two groups, but caesarean section rate was higher in the control group.
Conclusion
Opiate-addicted mothers have adverse perinatal outcomes even on MSPs. In addition to the drug effect associated social, relationship and accommodation problems should also be addressed as they may affect the outcome. Pregnancy care for these women needs to continue to develop to improve overall outcomes.
Similar content being viewed by others
References
Kraus L, Augustin R, Frischer M, Kummler P, Uhl A, Wiessing L (2003) Estimating the prevalence of problem drug use at national level in countries of the European Union and Norway. Addiction 98:471–485
Department of Health (England) and the Devolved Administrations (2007) Drug misuse and dependence: UK guidelines on clinical management. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, London. The Stationary Office, London
Clarke K, Formby J (2000) Feeling good, doing fine. Druglink 15:10–13
Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, Lindow SW (2005) Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 126:170–175
Day E, George S (2005) Management of drug misuse in pregnancy. Adv Psychiatric Treat 11:253–261
Hulse GK, Milne E, English DR, Holman CDJ (1997) The relationship between maternal use of heroin and methadone in infant birth weight. Addiction 92:1571–1579
Little BB, Snell LM, Klein VR, Gistrap LC 3rd, Knoll KA, Breckenridge JD (1990) Maternal and fetal effects of heroin addiction during pregnancy. J Reprod Med 35:159–162
Finnegan LP, Kron RE, Connaughton JF, Emich JP (1975) Assessment and treatment of abstinence in the infant of the drug dependant mother. Int J Clin Pharmacol Biopharm 12(1–2):19–32
Osborn DA, Jeffery HE, Cole M (2005) Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev (3):CD002059. doi:10.1002/14651858.CD002059.pub2 (Citation as instructed)
Kashiwagi M, Arlettaz R, Lauper U, Zimmermann R, Hebisch G (2005) Methadone maintenance program in a Swiss perinatal center: (I): management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 84(2):140–144
Ward J, Mattick RP, Hall W (1998) Methadone maintenance during pregnancy. In: Ward J, Mattick RP, Hall W (eds) Methadone maintenance treatment and other opioid replacement therapies. Harwood Academic Publishers, Amsterdam, pp 397–418
Llewelyn RW (2000) Substance abuse in pregnancy: the team approach to antenatal care. Obstet Gynaecol 2(1):11–16
Hepburn M (1997) Drugs of addiction. In: Cockburn F (ed) Advances in perinatal medicine. Parthenon Publishing, Carnforth, London
Minozzi S, Amato L, Vecchi S, Davoli M (2008) Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev (2):CD006318. doi:10.1002/14651858.CD006318.pub2
Greater London Alcohol and Drug Alliance (GLADA) (2005). Alcohol and drugs in London: improving the options for women.Greater London Authority, London. http://legacy.london.gov.uk/mayor/health/docs/womens_report.pdf
Management of opioid drug users/methadone programme patients, April 2009. Guy’s and St. Thomas’ Hospitals NHS Foundation Trust, London
(2008) Guidelines for the woodvine maternity liaison service (North): a joint substance misuse service between South London & Maudsley and Guys & St Thomas’ Foundation NHS Trusts, March 2008
Boer K, Smith BJ, van Huis AM, Hogerzeil HV (1994) Substance use in pregnancy: do we care? Acta Paediatr 83(s404):65–71
Kakko J, Heilig M, Sarman I (2008) Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 1:69–78
Kuschel C (2007) Managing drug withdrawal in the newborn infant. Semin Fetal Neonat Med 12:127–133
Jansson LM, Velez M (2012) Neonatal abstinence syndrome. Curr Opin Pediatr 24(4):252–258
(2010) Effects of maternal active and passive on fetal and reproductive health: Royal College of Physicians, 11 St Andrews Place, London NW1 4LE, March 2010. http://www.rcplondon.ac.uk
(2004) Centre for disease control and prevention (CDC): CDC morbidity and mortality weekly report (MMWR: October 8, 2004). Smoking during pregnancy, United States, 1990–2002, vol 3, no 39, pp 911–915
(2010) National institute for health and clinical excellence (NICE): quitting smoking in pregnancy and following childbirth (PH26), Public Health Guidance PH26, June 2010. http://guidance.nice.org.uk/PH26
Yerushalmy J (1971) The relationship of parents’ cigarette smoking to outcome of pregnancy—implications as to the problem of inferring causation from observed associations. Am J Epidemiol 93:443–456
Beckman C, Demilew J (2001) Audit of ‘unbooked women’ in maternity services, 2000. King’s College Hospital, London
Acknowledgments
One of the authors (EG) carried out this study as a BSc project under supervision of AA under the auspices of Maternal and Fetal Research, King’s College London. This was granted a BSc Degree, University of London. AD acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
See Table 5
Rights and permissions
About this article
Cite this article
Greig, E., Ash, A. & Douiri, A. Maternal and neonatal outcomes following methadone substitution during pregnancy. Arch Gynecol Obstet 286, 843–851 (2012). https://doi.org/10.1007/s00404-012-2372-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-012-2372-9